Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma. Diggs A, Sia TY, Huang Y, Gockley A, et al. Gynecol Oncol 2022 Jun 2. pii: S0090-8258(22)00329.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Diggs A, Sia TY, Huang Y, Gockley A, et al. Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma. Gynecol Oncol 2022 Jun 2. pii: S0090-8258(22)00329.
PMID: 35660331